← All trials
NCT03214731
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2018
- Primary completion
- Nov 1, 2020
- Completion date
- Nov 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 90
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Nanchang UniversityCollaborator
- Central South UniversityCollaborator
- Fujian Medical UniversityCollaborator
- Ningxia Medical UniversityCollaborator
- Sun Yat-Sen UniversityReponsible party - principal investigator
- China Medical UniversityCollaborator
- The First People's Hospital of Yunan ProvinceCollaborator
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.